Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
PharmaCielo ( (TSE:PCLO) ) has shared an update.
PharmaCielo Ltd., the Canadian parent of Colombia-based cannabis cultivator and producer PharmaCielo Colombia Holdings S.A.S., has issued 12,153,937 common shares at an effective price of $0.08 to satisfy $972,317.12 in semi-annual interest owed on its 11% secured debentures, following approval from the TSX Venture Exchange. The share-for-debt transaction, which includes issuances to related parties but falls below the threshold requiring a formal valuation or minority shareholder approval, helps preserve cash for operations as the company prepares for its April 2, 2026 annual general and special meeting in Toronto, where shareholders will address director elections, auditor appointments and other routine matters.
The move to pay debenture interest in shares rather than cash underscores PharmaCielo’s ongoing balance sheet management, potentially reducing near-term cash outflows while moderately diluting existing shareholders. The upcoming AGM provides a forum for investors to review the company’s governance and financial strategy as it operates within the competitive global medicinal and commercial cannabis supply market.
The most recent analyst rating on (TSE:PCLO) stock is a Sell with a C$0.06 price target. To see the full list of analyst forecasts on PharmaCielo stock, see the TSE:PCLO Stock Forecast page.
Spark’s Take on PCLO Stock
According to Spark, TipRanks’ AI Analyst, PCLO is a Neutral.
The score is held down primarily by weak financial performance (declining revenue, large losses, negative equity, high leverage, and negative free cash flow). Technicals also point to a weak trend with negative momentum signals. Valuation is the main offset, with a low P/E, but it is not enough to outweigh the financial and trend risks.
To see Spark’s full report on PCLO stock, click here.
More about PharmaCielo
PharmaCielo Ltd. is a Canada-headquartered global cannabis company focused on the ethical and sustainable cultivation, processing and supply of all-natural, pharmaceutical-grade medicinal and commercial dried cannabis flower and cannabis products. Its principal wholly owned subsidiary, PharmaCielo Colombia Holdings S.A.S., operates from a cultivation and processing centre in Rionegro, Colombia, supplying large channel distributors.
Average Trading Volume: 111,682
Technical Sentiment Signal: Hold
Current Market Cap: C$9.69M
For detailed information about PCLO stock, go to TipRanks’ Stock Analysis page.